Patent intelligence · US
US 11413255
Multifunctional cytoprotectant for treatment of pathogenic processes mediated by oxidative stress and toxic electrophiles
Multifunctional cytoprotectant for treatment of pathogenic processes mediated by oxidative stress and toxic electrophiles
Patent details — US 11413255
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 16, 2022
- Expiration
- Aug 11, 2042
- Applicant
- Montefiore Medical Center
- Claims
- 10
- CPC classes
- A61K, A61K31/05, A61K31/095, A61K31/12
Quick answer
US 11413255 (Multifunctional cytoprotectant for treatment of pathogenic processes mediated by oxidative stress and toxic electrophiles) is held by Montefiore Medical Center. Status: granted. Granted Aug 16, 2022. Expires Aug 11, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Montefiore Medical Center
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/05, A61K31/095, A61K31/12, A61K31/167, A61K31/36
More from Montefiore Medical Center
Related pharmaceutical patents in our USPTO index.
-
US 12391663
Isoindolinone compounds
granted -
US 12378199
Rigidified pentadentate chelating agents useful for the [Al18F]2+ labelling of biomolecules
granted -
US 12280029
Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
granted -
US 12263143
Ionic channel modulation as a method for treating tumors through inflammasome activation
granted -
US 12257247
Targeted degradation of VAV1
granted -
US 12214218
Perfusion modulated tumor dose sculpting with single dose radiotherapy
granted -
US 12070628
Low energy immune priming for treating cancer and metastasis
granted -
US 12011619
Low intensity focused ultrasound for treating cancer and metastasis
granted
Frequently asked questions
What is US patent 11413255?
US 11413255 (Multifunctional cytoprotectant for treatment of pathogenic processes mediated by oxidative stress and toxic electrophiles) is held by Montefiore Medical Center. Status: granted. Granted Aug 16, 2022. Expires Aug 11, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11413255?
Montefiore Medical Center is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 72 pharmaceutical patents for this assignee.
When does US 11413255 expire?
Our index shows an expiration date of Aug 11, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.